Sucampo Pharmaceuticals, Inc. Contracts & Agreements

Supplemental Indenture, dated as of February 13, 2018, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on February 13, 2018)

Agreement and Plan of Merger, dated as of December 23, 2017, by and among Sucampo Pharmaceuticals, Inc., Mallinckrodt plc and Sun Acquisition Co (Filed With SEC on December 26, 2017)

Second Amendment to Office Lease Agreement, dated as of September 5, 2017, by and between the Registrant and Four Irvington Centre Associates, LLC (Filed With SEC on November 1, 2017)

Separation Agreement, dated as of May 17, 2017, between the Company and Andrew Smith (Filed With SEC on August 2, 2017)

Separation Agreement, dated as of June 6, 2017, between the Company and Matthias Alder (Filed With SEC on August 2, 2017)

Executive Employment Agreement, dated as of March 7, 2017, between the Company and Jones Woodrow Bryan, Jr (Filed With SEC on August 2, 2017)

SUCAMPOPHARMACEUTICALS, INC. AMENDEDAND RESTATED 2006 EMPLOYEESTOCK PURCHASE PLAN ADOPTEDBY THE BOARD OF DIRECTORS: JUNE5, 2006 APPROVEDBY THE STOCKHOLDERS: SEPTEMBER 5, 2006... (Filed With SEC on March 8, 2017)

SucampoPharmaceuticals, Inc. 2016 Equity Incentive Plan EmployeeRestricted Stock Unit Award Grant Notice (Filed With SEC on March 8, 2017)

SUCAMPO PHARMACEUTICALS, INC. AND U.S. BANK NATIONALASSOCIATION, as Trustee INDENTURE Dated as ofDecember 27, 2016 3.25% Convertible Senior Notes due 2021 TABLE OF CONTENTS (Filed With SEC on December 27, 2016)

INDEMNIFICATION AGREEMENT (Filed With SEC on November 9, 2016)

AMENDED AND RESTATED EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on November 9, 2016)

AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT (Filed With SEC on November 9, 2016)

SUCAMPO PHARMACEUTICALS, INC. 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 18, 2016 APPROVED BY THE STOCKHOLDERS: JUNE 2, 2016 TERMINATION DATE: APRIL 18,... (Filed With SEC on August 3, 2016)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on May 5, 2016)

OPTION AND COLLABORATIONAGREEMENT (Filed With SEC on May 5, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 5, 2016)

SEPARATION AGREEMENT ANDRELEASES (Filed With SEC on May 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2016)

Sucampo Pharmaceuticals, Inc. Non-Employee Director Compensation Summary (Filed With SEC on March 11, 2016)

Sucampo Pharmaceuticals, Inc. Duration-Based Stock Option IncentiveAward Stock Option Agreement Terms and Conditions (Filed With SEC on March 11, 2016)

AMENDMENT 1 TO THE LICENSE, DEVELOPMENT, COMMERCIALIZATION ANDSUPPLY AGREEMENT FOR LUBIPROSTONE (Filed With SEC on March 11, 2016)

FIRST AMENDMENT TO OFFICE LEASE AGREEMENT (Filed With SEC on November 4, 2015)

STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 among Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. and R-Tech Ueno, Ltd. (Filed With SEC on November 4, 2015)

SHARE PURCHASE AGREEMENT (Filed With SEC on November 4, 2015)

OFFICE LEASE AGREEMENT By and Between FOUR IRVINGTON CENTRE ASSOCIATES,LLC ("Landlord") and SUCAMPO PHARMACEUTICALS, INC. ("Tenant") ****** Four IrvingtonCentre 805 King Farm... (Filed With SEC on August 5, 2015)

LICENSE, DEVELOPMENT, COMMERCIALIZATIONAND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR PEOPLE’S REPUBLIC OF CHINA by and between: Harbin Gloria Pharmaceuticals Co.,Ltd. and SUCAMPO AG... (Filed With SEC on August 5, 2015)

TRANSFER AND TERMINATION AGREEMENT DATED May 6, 2015 ("EffectiveDate") (Filed With SEC on August 5, 2015)

4,000,000 of Shares Sucampo Pharmaceuticals, Inc. UNDERWRITING AGREEMENT (Filed With SEC on March 30, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2015)

Exhibit 10.88*** Text Omitted and Filed SeparatelyConfidential Treatment RequestedUnder 17 C.F.R. 200.80(b)(4) and 240.24b-2 STIPULATION AND LICENSE AGREEMENT (Filed With SEC on March 9, 2015)

MANUFACTURING AND SUPPLY AGREEMENT BY AND BETWEEN SUCAMPO AG AND PAR PHARMACEUTICAL, INC. DATED AS OF FEBRUARY 5, 2015 (Filed With SEC on March 9, 2015)

LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on November 7, 2014)

SETTLEMENT AND LICENSE AGREEMENT (Filed With SEC on November 7, 2014)

MANUFACTURING AND SUPPLY AGREEMENT BY AND BETWEEN SUCAMPO AG AND PAR PHARMACEUTICAL, INC. DATED AS OF SEPTEMBER 30, 2014 (Filed With SEC on November 7, 2014)

AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT AND SUPPLEMENTAL AGREEMENT (Filed With SEC on November 7, 2014)

AMENDMENT NO. 1 TO AGREEMENT (Filed With SEC on November 7, 2014)

AMENDMENT NO. 1 TO SUPPLY AGREEMENT AND SUPPLY AND PURCHASE AGREEMENT AND ADDENDUM TO SUPPLY & PURCHASE AGREEMENT (Filed With SEC on November 7, 2014)

Confidential Peter Greenleaf Employment AgreementFebruary 10, 2014FINAL (Filed With SEC on March 12, 2014)

Confidential1 Ryuji Ueno (Filed With SEC on March 12, 2014)

MASTER LEASE AGREEMENT (Filed With SEC on May 10, 2012)

Loan Guarantee and DevelopmentAgreement (Filed With SEC on March 15, 2012)

EMPLOYMENTAGREEMENT (Filed With SEC on March 15, 2012)

SETTLEMENT AND MUTUAL RELEASE AGREEMENT (Filed With SEC on November 9, 2011)

Sucampo Pharmaceuticals, Inc. Duration and Performance-Based Stock Option Incentive Award Stock Option Agreement Terms and Conditions (Filed With SEC on May 6, 2011)

Special Agreement (Filed With SEC on March 8, 2011)

Agreement on Bank Overdrafts (Through an Account Used Exclusively for the Purpose of Bank Overdrafts) (Customer Copy) (Filed With SEC on March 8, 2011)

STOCKPURCHASE AGREEMENT BYAND AMONG SUCAMPOPHARMACEUTICALS, INC., AMBRENTINVESTMENTS S. R.L., RYUJIUENO, AS TRUSTEE OF THE RYUJI UENO REVOCABLE TRUST UNDER TRUST AGREEMENTDATED... (Filed With SEC on December 29, 2010)

SUBORDINATED UNSECUREDPROMISSORY NOTE (Filed With SEC on December 29, 2010)

NON-COMPETITIONAGREEMENT (Filed With SEC on December 29, 2010)

Condensed Consolidated Financial Statements (Unaudited) (Filed With SEC on November 6, 2009)

SUCAMPO PHARMACEUTICALS, INC. Compensation Program for Non-Employee Directors (Adopted on October 7, 2009) (Filed With SEC on October 8, 2009)

Nonstatutory Stock Option Agreement for Non-Employee Directors Granted Under 2006 Stock Incentive Plan (Filed With SEC on October 8, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on October 5, 2009)

[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of The... (Filed With SEC on May 11, 2009)

Page 1 of 41 (Filed With SEC on May 11, 2009)

LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR JAPAN (Filed With SEC on March 16, 2009)

LUBIPROSTONE EXCLUSIVE MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on March 16, 2009)

ADDENDUM TO AMENDED AND RESTATED PATENT ACCESS AGREEMENT: REDUCTION OF ROYALTIES WITH RESPECT TO SPL TERRITORY (Filed With SEC on February 20, 2009)

AGREEMENT AND PLAN OF REORGANIZATION (Filed With SEC on December 29, 2008)

ASSIGNMENT AND ASSUMPTION AGREEMENT (Filed With SEC on December 29, 2008)

AMENDED AND RESTATED (Filed With SEC on December 11, 2008)

SEPARATION AGREEMENT AND GENERAL RELEASE (Filed With SEC on July 28, 2008)

INDEPENDENT CONTRACTOR AGREEMENT (Filed With SEC on July 28, 2008)

INDEMNIFICATION AGREEMENT (Filed With SEC on July 22, 2008)

INDEMNIFICATION AGREEMENT (Filed With SEC on May 14, 2008)

In thousands, except share data (Filed With SEC on March 27, 2008)

INDEMNIFICATION AGREEMENT (Filed With SEC on November 14, 2007)

SUCAMPO PHARMACEUTICALS, INC. (Filed With SEC on November 14, 2007)

Sucampo Pharmaceuticals, Inc. Class A Common Stock UNDERWRITING AGREEMENT dated [___] , 2007 Cowen and Company, LLC (Filed With SEC on July 30, 2007)

SPI-8811 (cobiprostone) for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders... (Filed With SEC on July 17, 2007)

SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with... (Filed With SEC on June 25, 2007)

SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with... (Filed With SEC on May 14, 2007)

SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and... (Filed With SEC on February 1, 2007)

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)

Confidentialmaterials omitted and filed separately with the Securities andExchange Commission. Asterisks denote omissions. (Filed With SEC on October 25, 2006)

SUCAMPO PHARMACEUTICALS, INC. 2006 STOCK INCENTIVE PLAN RESTATED (Filed With SEC on October 20, 2006)

SUCAMPO PHARMACEUTICALS, INC. 2006 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on October 20, 2006)

SUCAMPO PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2006 Stock Incentive Plan (Filed With SEC on October 20, 2006)

SUCAMPO PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2006 Stock Incentive Plan (Filed With SEC on October 20, 2006)

SUCAMPO PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2006 Stock Incentive Plan (Filed With SEC on October 20, 2006)

INDEMNIFICATION AGREEMENT (Filed With SEC on October 20, 2006)

SUCAMPO PHARMACEUTICALS, INC. Non-Employee Director Compensation Program (Filed With SEC on August 11, 2006)

EMPLOYMENT AGREEMENT (Filed With SEC on August 11, 2006)

Amended and Restated (Filed With SEC on August 11, 2006)

SUCAMPO PHARMACEUTICALS, INC AMENDED & RESTATED 2001 STOCK INCENTIVE PLAN (Filed With SEC on June 19, 2006)

Executive Salary Mariam E. Morris ChiefFinancial Officer and Treasurer $ 160,000 Brad E. Fackler ExecutiveVice President of Commercial Operations $ 220,000 Gayle R. Dolecek Senior... (Filed With SEC on June 19, 2006)

INDEMNIFICATION AGREEMENT (Filed With SEC on June 19, 2006)

Shares of Class A Common Stock (assuming conversion of all outstanding sharesName of convertible preferred stock)Astellas Pharma, Inc. 147,500 Mitsubishi UFJ Capital Co., Ltd.... (Filed With SEC on June 19, 2006)

4733 BETHESDA AVENUE (Filed With SEC on June 19, 2006)

SUBLEASE AGREEMENT (Filed With SEC on June 19, 2006)

Confidential Materials omitted and filed separately with the (Filed With SEC on June 19, 2006)

ConfidentialMaterials omitted and filed separately with the Securities and ExchangeCommission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)

ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. (Filed With SEC on June 19, 2006)

Confidential Materials omitted and filed separately with the Exhibit 10.26 Securities and Exchange Commission. Asterisks denote omissions. SERVICE AGREEMENT (Filed With SEC on June 19, 2006)

Category

Industry

Companies

Contracts

Sucampo Pharmaceuticals, Inc. Contracts & Agreements